title: Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).
authors.affiliation: Hematology and Medical Oncology, Winship Cancer Institute of Emory University , Atlanta, GA , USA.
authors.forename: Nabil F
authors.initials: NF
authors.lastname: Saba
keywords: EGFR; HER3 inhibitors; Nrg1; cetuximab; squamous cell carcinoma of the head and neck